Clinical trial

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

NCT04954742

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-04-13

PhasePHASE4

Study timeline

Study start (actual)2022-04-13Date precision: day

Registry last updated2026-06-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Primary Pulmonary Arterial Hypertensionunresolved

Chronic Thromboembolic Pulmonary Hypertensionunresolved

Interventions

RiociguatDRUG · verified · RxNorm: riociguat

Sponsors & collaborators

Heidelberg Universitylead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

HeidelbergGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04954742 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.